245 related articles for article (PubMed ID: 37501397)
21. PD-L1 Expression and CD8
Petitprez F; Fossati N; Vano Y; Freschi M; Becht E; Lucianò R; Calderaro J; Guédet T; Lacroix L; Rancoita PMV; Montorsi F; Fridman WH; Sautès-Fridman C; Briganti A; Doglioni C; Bellone M
Eur Urol Focus; 2019 Mar; 5(2):192-196. PubMed ID: 28753812
[TBL] [Abstract][Full Text] [Related]
22. Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy.
Morrissey SM; Yan J
Trends Cancer; 2020 Jul; 6(7):550-558. PubMed ID: 32610067
[TBL] [Abstract][Full Text] [Related]
23. PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8
Chen J; Song Y; Miao F; Chen G; Zhu Y; Wu N; Pang L; Chen Z; Chen X
Cancer Sci; 2021 Sep; 112(9):3437-3454. PubMed ID: 34152672
[TBL] [Abstract][Full Text] [Related]
24. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.
Qiu Y; Yang Y; Yang R; Liu C; Hsu JM; Jiang Z; Sun L; Wei Y; Li CW; Yu D; Zhang J; Hung MC
Oncogene; 2021 Aug; 40(31):4992-5001. PubMed ID: 34172932
[TBL] [Abstract][Full Text] [Related]
25. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression.
Luo C; Xin H; Zhou Z; Hu Z; Sun R; Yao N; Sun Q; Borjigin U; Wu X; Fan J; Huang X; Zhou S; Zhou J
Hepatology; 2022 Oct; 76(4):982-999. PubMed ID: 35106794
[TBL] [Abstract][Full Text] [Related]
26. Prostate carcinoma cell-derived exosomal MicroRNA-26a modulates the metastasis and tumor growth of prostate carcinoma.
Wang X; Wang X; Zhu Z; Li W; Yu G; Jia Z; Wang X
Biomed Pharmacother; 2019 Sep; 117():109109. PubMed ID: 31229922
[TBL] [Abstract][Full Text] [Related]
27. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
28. Clinical Significance of PD-L1
Theodoraki MN; Yerneni SS; Hoffmann TK; Gooding WE; Whiteside TL
Clin Cancer Res; 2018 Feb; 24(4):896-905. PubMed ID: 29233903
[TBL] [Abstract][Full Text] [Related]
29. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
Chen T; Dong Y; Wu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
[TBL] [Abstract][Full Text] [Related]
30. Cancer cell-derived exosomal miR-20a-5p inhibits CD8
Li W; Han G; Li F; Bu P; Hao Y; Huang L; Bai X
Cancer Sci; 2024 Feb; 115(2):347-356. PubMed ID: 38129137
[TBL] [Abstract][Full Text] [Related]
31. Tumor-derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer.
Wu Y; Fu H; Hao J; Yang Z; Qiao X; Li Y; Zhao R; Lin T; Wang Y; Wang M
Front Immunol; 2024; 15():1342728. PubMed ID: 38562933
[TBL] [Abstract][Full Text] [Related]
32. Phototheranostic Metal-Phenolic Networks with Antiexosomal PD-L1 Enhanced Ferroptosis for Synergistic Immunotherapy.
Xie L; Li J; Wang G; Sang W; Xu M; Li W; Yan J; Li B; Zhang Z; Zhao Q; Yuan Z; Fan Q; Dai Y
J Am Chem Soc; 2022 Jan; 144(2):787-797. PubMed ID: 34985903
[TBL] [Abstract][Full Text] [Related]
33. Orexin A Suppresses the Expression of Exosomal PD-L1 in Colon Cancer and Promotes T Cell Activity by Inhibiting JAK2/STAT3 Signaling Pathway.
Wen J; Chang X; Bai B; Gao Q; Zhao Y
Dig Dis Sci; 2022 Jun; 67(6):2173-2181. PubMed ID: 34097168
[TBL] [Abstract][Full Text] [Related]
34. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
35. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
36. ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression.
Zhang W; Zhong W; Wang B; Yang J; Yang J; Yu Z; Qin Z; Shi A; Xu W; Zheng C; Schuchter LM; Karakousis GC; Mitchell TC; Amaravadi R; Herlyn M; Dong H; Gimotty PA; Daaboul G; Xu X; Guo W
Dev Cell; 2022 Feb; 57(3):329-343.e7. PubMed ID: 35085484
[TBL] [Abstract][Full Text] [Related]
37. Enhancing the anti-leukemia immunity of acute lymphocytic leukemia-derived exosome-based vaccine by downregulation of PD-L1 expression.
Huang F; Li Z; Zhang W; Li J; Hao S
Cancer Immunol Immunother; 2022 Sep; 71(9):2197-2212. PubMed ID: 35092480
[TBL] [Abstract][Full Text] [Related]
38. Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer.
Shi X; Sun J; Li H; Lin H; Xie W; Li J; Tan W
Prostate; 2020 Aug; 80(11):811-823. PubMed ID: 32427375
[TBL] [Abstract][Full Text] [Related]
39. PD-L1
Sun Y; Guo J; Yu L; Guo T; Wang J; Wang X; Chen Y
Cell Mol Immunol; 2021 Oct; 18(10):2402-2409. PubMed ID: 32606317
[TBL] [Abstract][Full Text] [Related]
40. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets.
Liang B; Hu X; Ding Y; Liu M
J Cell Physiol; 2021 Jun; 236(6):4138-4151. PubMed ID: 33275291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
